Cinvex and Abstal, the new products of Er-Kim İlaç, were introduced to the market


Active Substance



Er-Kim İlaç obtained approval reimbursement for “Cinvex 250 mcg/5 ml vial”, its first local manufacturing product, with the active ingredient of palonosetron which is used in the treatment of chemotherapy induced nausea and vomiting, and started to supply the product to wholesalers as of May 2016.

“Abstral Sublingual Tablets”, another new product of Er-Kim İlaç, is a drug produced by the cooperating company Kyowa Kirin with fentanyl as active substance. Used for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, Abstral Sublingual Tablets in packs containing 10 tablets of 100 mcg, 200 mcg, 400 mcg and 800 mcg dosage forms were approved for reimbursement as of January 20 2016 and introduced to market for use in June 2016.